Because glucokinase is a metabolic sensor involved in the regulated release of insulin, we have investigated the acute actions of novel glucokinase activator compound 50 (GKA50) on islet function. Insulin secretion was determined by enzyme-linked immunosorbent assay, and microfluorimetry with fura-2 was used to examine We show that GKA50 is a glucose-like activator of ␤-cell metabolism in rodent and human islets and a Ca 2؉ -dependent modulator of insulin secretion.
G lucokinase (EC2.7.1.1, hexokinase IV or D) catalyzes the phosphorylation of glucose to glucose-6-phosphate in glucosensitive cells of the pancreas, liver, hypothalamus, anterior pituitary gland, and entero-endocrine K and L cells (1) (2) (3) . Although all hexokinases can catalyze this reaction, glucokinase has an affinity for glucose that is within the physiological plasma glucose range (half-saturation level for glucose [S 0.5 ] of ϳ6 mmol/l), and unlike the other hexokinases, glucokinase is not inhibited by glucose-6-phosphate (4 -6) . Unusually for a monomeric enzyme, glucokinase shows positive substrate cooperativity (Hill coefficient ϭ 1.7) and as such has sigmoidal, as opposed to classical hyperbolic, kinetics (7) . These unique kinetic properties result in glucokinase having a high "control strength" over the responses of glucosensitive cells and have led to it being termed the "glucose sensor" (8) . This concept is reinforced by the identification of Ͼ200 naturally occurring mutations of glucokinase, the majority of which have a dramatic effect on phenotype and have been linked with both hypo-and hyperglycemic disorders (9 -11) . In humans, inactivation of one glucokinase allele leads to maturity-onset diabetes of the young 2, whereas loss of both alleles is associated with permanent neonatal diabetes (12) (13) (14) (15) . Activating mutations of glucokinase are much rarer and result in congenital hyperinsulinism, which is typified by the inappropriate insulin release for the level of glycemia (16 -19) . In mice, global or pancreatic ␤-cell disruption of the glucokinase gene is lethal within days of birth because of the development of severe diabetes (20, 21) . In contrast, heterozygous-null mice are only modestly hyperglycemic (22, 23) . Heterozygous disruption of hepatic glucokinase causes a decrease in the effectiveness of glucose on hepatic glucose production and utilization (23) . In contrast, a ␤-cell selective decrease in glucokinase activity causes decreased insulin secretion but no changes in fasting plasma glucose levels or glucose tolerance (23) .
The prominent role of glucokinase in glucose sensing and its dual role in hepatocytes and ␤-cells make glucokinase a promising drug target for diabetes therapy. Several groups have independently reported on a number of synthetic low-molecular weight molecules that act as activators of glucokinase (23) (24) (25) (26) (27) (28) (29) (30) (31) . We have recently described a series of glucokinase activators (GKAs), GKA1, -2, -22, and -50, that can modulate hepatic glucokinase activity in vitro and potently reduce blood glucose levels in vivo (25, 29, 30, 32) . Of this range of compounds, GKA50
is significantly the most potent at lowering plasma glucose levels and has chemical properties that make it worthy of further study (29, 30, 32) . However, the effects of this compound on insulin release in vitro or islet function have not yet been described. Here, we have used rodent and human islets and MIN6 cells to show that GKA50 is a Ca 2ϩ -dependent activator of insulin-secreting cells.
RESEARCH DESIGN AND METHODS
Isolation of pancreatic islets. Male Sprague-Dawley rats (230 -280 g) were humanely killed according to Home Office-approved procedures. The pancreas was then removed and partially digested by incubating at 37°C in HEPES-balanced Krebs-Ringer phosphate buffer (KRH), composed of 129 mmol/l NaCl, 5 mmol/l NaHCO 3 , 4.8 mmol/l KCl, 1.2 mmol/l KH 2 PO 4 , 1.2 mmol/l MgSO 4 , 10 mmol/l HEPES, 2.5 mmol/l CaCl 2 , 5.6 mmol/l glucose, and 0.1% BSA (pH 7.4, NaOH) supplemented with 1.38 mg/ml liberase Rodent Islet isolation formulation (Roche, Welwyn Garden City, U.K.) and 1.83 mg/ml each of egg white and soybean trypsin inhibitors. The pancreas was further digested by incubating at 37°C in KRH supplemented with 0.72 mg/ml liberase RI and 1.55 mg/ml each of egg white and soybean trypsin inhibitors until islets were dissociated from the exocrine tissue. Islets were handpicked and cultured for 1-3 days in RPMI 1640 (5 mmol/l glucose; Invitrogen, Paisley, Scotland, U.K.), 10% FCS (Invitrogen), and penicillin/streptomycin (100 units/ ml, 0.1 mg/ml; Invitrogen) at 37°C in a 5% CO 2 humidified atmosphere.
Islets from C57BL6 mice were isolated using a similar protocol except that volumes were reduced accordingly and culture was in 11 mmol/l glucose RPMI 1640. Human islets were obtained on separate occasions from two donors and provided by United Kingdom Human Tissue Bank (Leicester, U.K.) and isolated in the Islet Research Laboratory (Worcester, U.K.) in accordance with current ethical guidelines pertaining to the use of human tissue in research. Cold ischemia time was 10 h. Islets were isolated as previously described (33) and, upon receipt, were cultured in RPMI (11 mmol/l glucose; Invitrogen), 10% FCS, and penicillin/streptomycin (100 units/ml, 0.1 mg/ml) at 30°C in a 5% CO 2 for at least 2 h before glucose-stimulated insulin secretion (GSIS) experiments. MIN6 cell culture. MIN6 cells (passages [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] (34, 35) were maintained in Dulbecco's modified Eagle's medium (DMEM; 25 mmol/l glucose; Invitrogen) supplemented with 15% FCS, penicillin/streptomycin (100 units/ml, 0.1 mg/ ml), 2 mmol/l/l L-glutamine, and 5 l/l 2-mercaptoethanol. Cells were incubated at 37°C in a 5% CO 2 humidified incubator. The culture medium was changed every 48 -72 h. Insulin secretion and protein content assay. GSIS from MIN6 cells and islets was determined using a static incubation protocol. For MIN6, cells were cultured in 96-well plates until ϳ80% confluent, and the medium was changed every 48 -72 h. On the day of experiment, growth medium was removed, and the cells were washed twice with glucose-free KRH supplemented with 0.1% radioimmunoassay grade BSA. Cells were preincubated for 1 h in 5% CO 2 at 37°C in KRH (1 mmol/l glucose). Incubation medium was removed, and the cells were washed once in glucose-free KRH. The cells were then incubated for 1 h in KRH containing the appropriate treatment. There were two modifications to this standard protocol. First, when using a high extracellular concentration of K ϩ , NaCl was replaced by equimolar KCl in the KRH buffer; second, when investigating the action of GKA50 in the presence of glucose analogs, cells were preincubated in a glucose-free KRH for 30 min. For all experiments, incubation medium was collected, and the amount of secreted insulin was determined using ELISA (standard and high range kits; Mercodia, U.K.). For those experiments in which protein content was measured, MIN6 cells were solubilized by addition of 2% Triton X-100 solution, and the protein content was determined using the Bradford method (Bio-Rad, Hemel Hempstead, U.K.). 
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Insulin secretion from isolated islets was determined using a similar protocol. Briefly, the islets (rat, mouse, and human) were handpicked in groups of three and incubated in KRH (1 and 3 mmol/l glucose for rodent and human islets, respectively) for 30 or 60 min at 37°C and in 5% CO 2 . After the appropriate preincubation period, KRH containing the appropriate treatment was added, and the islets were incubated for 1-2 h at 37°C and in 5% CO 2 . After incubation, the islets were centrifuged, the medium was collected, and the amount of secreted insulin was determined using standard ELISA or homogeneous time-resolved fluorescence assay (CisBio, Bognols/Cè ze, France). MIN6 and rodent islet datasets were obtained from three to six replications and repeated a minimum of three times. Human islet experiments were obtained from six replicates and repeated twice. Estimation of the free cytosolic Ca 2؉ concentration. To form small clusters of cells, MIN6 cells were cultured for 3-4 days in DMEM (as above) on poly-D-ornithine-coated coverslips (10 g/ml) in 24-well plates. Before experimentation, cells were loaded with Fura-2AM and pluronic acid (Invitrogen, Cambridge, U.K.) at a final concentration of 6 mol/l for 1 h at 37°C. Mouse islets were cultured for up to 36 h on fibronectin-coated coverslips (10 g/ml) in RPMI 1640 (5 mmol/l glucose, as above). Islets were loaded with Fura-2AM and pluronic acid to a final concentration of 6 mol/l and 0.06%, respectively, for 1 h at 37°C.
Estimated internal calcium concentration ([Ca 2ϩ ] i ) was measured by mounting the coverslips to form the base of a perifusion chamber (Harvard Apparatus, Edenbridge, U.K.). The cells were excited by 340 and 380 nm with a cycle time of 1.3 s using a monochromator (TILL Photonics, Planegg, Germany), attached to an Axiovert epifluorescence microscope (Zeiss, Jena, Germany). Images were collected by a Quantix CCD camera (Roper Scientific, Marlow, Bucks, U.K.) using the Metafluor software (Roper, U.K.). An in vitro calibration procedure was performed to determine estimated changes in [Ca 2ϩ ] i using the K d value of Fura-2 as 224 nmol/l (36).
The control perifusion solution contained 137 mmol/l NaCl, 5.36 mmol/l KCl, 0.81 mmol/l MgSO 4 , 0.34 mmol/l Na 2 HPO 4 , 0.44 mmol/l KH 2 PO 4 , 1.26 mmol/l CaCl 2 , 4.17 mmol/l NaHCO 3 , 10 mmol/l HEPES, and 2.02 mmol/l glucose (pH 7.4, NaOH). In solutions containing a high extracellular concentration of K ϩ , NaCl was replaced by equimolar KCl. Expression, purification, and activity of recombinant glucokinase. Measurements of recombinant enzyme activity of GKA50 for mouse and rat pancreatic glucokinase were performed using published procedures (25) . Statistics. Data are presented as means Ϯ SE. Comparisons were made using unpaired Student's t tests and one-way ANOVA, as appropriate. In Fig. 1B , data are plotted as fold change in insulin secretion against a log scale, upper and lower 95% confidence limits (CL) were calculated, and P values were derived from a two-sided Student's t test. Curves were fitted using the four-parameter Hill equation using Sigma Plot 2001 (Systat Software). Reagents. All reagents were of analytical grade and, except where noted, were from Sigma (Gillingham, U.K.). GKA50 was synthesized by AstraZeneca (30) .
RESULTS
Glucose-dependent modulation of insulin secretion by GKA50. The effects of GKA50 on GSIS from rodent and human islets and MIN6 cells are summarized in Figs. 1 and 2. These experiments revealed that GKA50 caused a shift in the measured glucose sensitivity, resulting in insulin release at lower glucose concentrations when compared with control islets/cells. Figure 1A and B summarizes the actions of 1 mol/l GKA50 on GSIS in mouse islets. These data show a clear leftward shift in the concentration response profile to glucose in the presence of GKA50. This was significant from sub-stimulatory glucose concentrations (Fig. 1B) to 10 mmol/l glucose (Fig. 1A) . Thus at 1 mmol/l glucose, we found that GKA50 (1 mol/l, all n ϭ 7; Fig. 1B ) evoked a 1.6-fold (95% CL 1-to 2.5-fold; P ϭ 0.04) increase in insulin release; at 2 mmol/l glucose, this was 3.4-fold (1.8-to 6.5-fold; P ϭ 0.002); at 3 mmol/l, this was 5.5-fold (2.3-to 12.9-fold; P ϭ 0.002); and at 5 mmol/l glucose, this was 8.3-fold (4.4-to 15.5-fold; P ϭ 0.0002). Thus, at these glucose concentrations, the magnitude of the GKA50 effect on insulin secretion was increased greatly at higher glucose concentrations. At 20 mmol/l glucose, although GKA50 was found to potentiate GSIS, this failed to reach statistical significance. In human islets, 1 mol/l GKA50 enhanced insulin release at 3 mmol/l glucose, and this was significant at 5 mmol/l glucose (Fig.  1C , representative of two separate experiments with different donors). The glucose sensitivity of rat islets (Fig.  1D ) and MIN6 cells ( Fig. 2A) was also similarly increased by GKA50 and was found to be significantly different at 3 and 2 mmol/l glucose, respectively. GSIS half-maximal effective concentration (EC 50 ) values were 9.3 Ϯ 0.1 mmol/l (n ϭ 5, vehicle control) versus 5.9 Ϯ 0.2 mmol/l (n ϭ 5, 1 mol/l GKA50 treated) for rat islets and 13.2 Ϯ 0.4 mmol/l (n ϭ 5, control) versus 2.5 Ϯ 0.2 mmol/l (n ϭ 7, GKA50 treated) for MIN6 cells. However, the maximal rate , control and treated, respectively) was not significantly affected by the addition of 1 mol/l GKA50 (Figs. 1D and 2A, respectively) .
After our initial evaluation in islets, we used MIN6 cells to investigate the concentration responsiveness to GKA50 (1 nmol/l to 10 mol/l) over a range of glucose concentrations (Fig. 2B) . In the absence of glucose, GKA50, even at concentrations up to 30 mol/l, was unable to modulate insulin secretion (not shown, n ϭ 3). However, in the presence of glucose (2-5 mmol/l), GKA50 exerted a concentration-dependent increase in insulin secretion with an EC 50 at 5 mmol/l glucose of 0.3 Ϯ 0.2 mol/l (Fig. 2B, n ϭ  4) . Depolarization of MIN6 cells with 40 mmol/l KCl was also found to enhance GSIS at all glucose concentrations tested (1-5 mmol/l), but there was no further action of 1 mol/l GKA50 on insulin release under these conditions (Fig. 2C, n ϭ 4) . These data suggest that modulation of voltage-dependent Ca 2ϩ influx is the principal mechanism associated with the action of GKA50 on insulin-secreting cells. (Fig. 3A , n ϭ 5). Although glucose was without effect on [Ca 2ϩ ] i at concentrations Ͻ5 mmol/l in control mouse islets, in the presence of 1 mol/l GKA50, changes in [Ca 2ϩ ] i were seen (Fig. 3B-D) . Thus, in the presence of 2 mmol/l glucose, 1 mol/l GKA50 caused an initial decrease in [Ca 2ϩ ] i followed by a marked, transient increase in [Ca 2ϩ ] i and then an elevated, sustained rise (Fig. 3B, n ϭ 3) . In the presence of 5 mmol/l glucose, 1 mol/l GKA50 typically caused an immediate increase in cytosolic Ca 2ϩ followed by [Ca 2ϩ ] i oscillations (Fig. 3C, n ϭ 4) . Elevating glucose from 5 to 10 mmol/l in (Fig. 3D , n ϭ 5). GKA50 (1 mol/l) was without effect on [Ca 2ϩ ] i in the absence of glucose (n ϭ 4) (not shown). Fig. 3E shows the results of experiments to examine interactions between GKA50 and glucose using rat islets. In these experiments, 1 mol/l GKA50 failed to elevate [Ca 2ϩ ] i at 2 mmol/l glucose but was effective at higher glucose concentrations (Fig. 3E, n ϭ 3) . Finally, we also found that GKA50 modulated glucose-dependent increases in [Ca 2ϩ ] i in MIN6 cells (n ϭ 15 from 16 cells, Fig. 3F ).
GKA50-versus tolbutamide-induced insulin release.
The sulfonylurea tolbutamide inhibits ATP-sensitive K ϩ (K ATP ) channels in ␤-cells and mediates insulin release through depolarization-dependent mechanisms. We therefore compared the actions of GKA50 and tolbutamide using MIN6 cells and rat islets. In MIN6 cells, both GKA50 (1 mol/l, Fig. 2 ) and tolbutamide (200 mol/l, Fig. 4A ) stimulated insulin release at 2 mmol/l glucose. However, in rat islets (Figs. 1D and 4B ), whereas tolbutamide initiated insulin release at 2 mmol/l glucose, GKA50 was without effect. Tolbutamide was unable to further enhance 1 mol/l GKA50-stimulated insulin secretion from either MIN6 cells or rat islets (Fig. 4A and B) . Figure 4C Figure 5A and B summarizes the actions of diazoxide (200 mol/l) on the inhibition of glucose-induced and 1 mol/l GKA50-induced insulin secretion in MIN6 cells (n ϭ 4) and rat islets (n ϭ 3), respectively. Because diazoxide hyperpolarizes the cell membrane potential via activation of K ATP channels, these effects were also associated with a reversible diazoxide-induced inhibition of cytosolic Ca 2ϩ (Fig. 5C, n ϭ 8) .
Inhibition of glucokinase by mannoheptulose and 5-TG was found to selectively inhibit 10 mol/l GKA50-induced insulin release, whereas the actions of 50 mol/l tolbutamide were not significantly affected (Fig. 5D, n ϭ 3) . Consistent with this data, measurements of [Ca 2ϩ ] i in mouse islets revealed that there was no significant action of the nonmetabolizable glucose analog, OMeG, on tolbutamide (100 mol/l)-induced rises in [Ca 2ϩ ] i (average change in [Ca 2ϩ ] i ϭ 111 Ϯ 16 nmol/l, n ϭ 10), whereas the actions of 1 mol/l GKA50 were attenuated (average change in [Ca 2ϩ ] i , 15 Ϯ 4 nmol/l, n ϭ 11) (Fig. 6) . 
GKA50 AND INSULIN RELEASE
DISCUSSION
Glucokinase is the glucose sensor for glucose-stimulated insulin release from ␤-cells and is the rate-limiting step in the glucose responsiveness of glucosensitive cells. Glucokinase therefore plays a major role in regulating carbohydrate metabolism in man, and defects in the glucokinase gene cause either hyperglycemia as a result of "loss of function" mutations or hypoglycemia through "gain of function" mutations.
Recently, several activators of glucokinase have been described in the literature (24 -32) , and the potential use of these agents, GKAs, in the therapeutic management of type 2 diabetes has been reviewed (37) (38) (39) . This group of compounds also includes the pyridine acid-based molecule, GKA50, which was recently shown to have a significant blood glucose-lowering efficacy in vivo in both control and insulin-resistant/hyperinsulinemic rats (32) . Because the actions of GKA50 include the modulation of insulin release in vivo, we have used isolated islets and MIN6 cells to examine the effects of GKA50 on both the regulated release of insulin and the control of intracellular Ca 2ϩ signaling events. In this series of experiments, we used mouse, rat, and human islets to show that GKA50 is a novel modulator of insulin release. We then used rat islets and MIN6 insulinsecreting cells to quantify the action of GKA50 on EC 50 values and maximal rates of insulin secretion. Although there may be some differences in the action of GKA50 across species (discussed below), we were able to make the following general conclusions. First, our data show that GKA50 was unable to elevate changes in the cytosolic Ca 2ϩ concentration ([Ca 2ϩ ] i ) or to promote insulin release in the absence of glucose, even up to activator concentrations as high as 30 mol/l. Second, GKA50-induced insulin release is dependent on an increase in [Ca 2ϩ ] i , and the threshold for this occurs at sub-stimulatory glucose concentrations. Collectively, these data indicate that GKA50 cannot initiate insulin release from ␤-cells and that its actions are strictly dependent on glucose availability. This is consistent with the modes of action of other GKAs (24, 28) and distinctly different from that of the sulfonylureas, which act independently of glucose availability (40 -45) . Third, GKA50, like other GKAs, caused a leftward shift in the EC 50 value for GSIS without affecting the maximal rates of insulin release. Finally, we describe for the first time that metabolic inhibition selectively eliminated the actions of GKA50 but not tolbutamide on insulin release and changes in [Ca 2ϩ ] i . Activation of K ATP channels by diazoxide also reversed the action of GKA50. these findings are consistent with the proposed actions of both agents. Through enhancing glucose metabolism, GKA50 acts in a glucose-dependent manner, and metabolic inhibition, resulting in the activation of K ATP channels, will eliminate these responses. Under the same conditions, the actions of tolbutamide are preserved because it acts directly on K ATP channels and is therefore independent of glucose availability. Consistent with this mechanism of action, we were also able to demonstrate that, in comparison with tolbutamide, GKA50-induced changes in [Ca 2ϩ ] i that were biphasic at low glucose concentrations and were significantly slower at reaching maximal responses (Fig.  4) .
The profile of GKA50-induced potentiation of insulin release is similar to that recently reported for LY2121260 (28) , but not that of Compound A, which has a profound effect on insulin release at low glucose concentrations and enhances insulin release at elevated glucose concentrations (31) . In rat islets, 1 mol/l GKA50, 1 mol/l LY2121260, and 10 mol/l RO-28-1675 had similar effects on insulin release at 4 -5 mmol/l glucose, increasing insulin release by approximately threefold, which is approximately equal to the amount of insulin released by 8 mmol/l glucose (24, 28) . Each of the compounds at 1 mol/l failed to further enhance insulin release in the presence of 15 mmol/l glucose or above.
Here, we also examined the actions of the GKA on mouse islets for the first time. The data in Figs. 1 and 2 appear to suggest differences in the sensitivity of rat and mouse islets to GKA50. In these experiments, whereas GKA50 failed to have any significant effect on insulin release at 2 mmol/l glucose in rat islets, a 3.5-fold increase in insulin release was induced by GKA50 at the same concentration in mouse islets. However, a closer review of the data reveals that this is not likely to be because of species differences in the sensitivity of GKA50 for glucokinase but rather a consequence of different [Ca 2ϩ ] i responses after stimulation. At 2 mmol/l glucose, mouse islets responded to GKA50 through a biphasic response in [Ca 2ϩ ] i , an initial decrease followed by a rise in cytosolic Ca 2ϩ . The first stage of this response is mediated by Ca 2ϩ sequestration to cytosolic stores (46, 47) and is then followed by Ca 2ϩ influx leading to insulin release. In rat islets, GKA50 caused only a sustained decreased [Ca 2ϩ ] i without a subsequent rise ( Fig. 3B and E) . This suggests that there is little difference in the sensitivity of glucokinase for GKA50 in rat versus mouse islets, and alone, it would not account for the differences in GKA50-mediated insulin release at this concentration of glucose. Recombinant enzyme activity assays of GKA50 for mouse and rat pancreatic glucokinase were very similar with GKA50, showing an EC 50 of 56 nmol/l (n ϭ 7, 95% CL 40 -79 nmol/l) at the mouse glucokinase and 65 nmol/l (n ϭ 23, 53-79 nmol/l) at the rat glucokinase. RO-28-1675 (24) and LY2121260 (28) also failed to evoke insulin release at 2 mmol/l glucose, although both agents were effective at sub-stimulatory glucose concentrations.
Given the powerful ability of GKAs to modulate insulin secretion, it is of benefit to understand how these molecules interact with, and subsequently activate, glucokinase and glucose metabolism. The exact mechanism is currently unknown. However, there is evidence to suggest that GKAs alter the kinetics by which glucokinase shifts between active and inactive conformations. Recently, the crystal structure of human glucokinase has been solved in the presence of glucose and a GKA (26) . The crystal structures revealed that glucokinase can adopt three distinct conformations termed closed, open, and "super open," which is inactive (26) . This hypothesis allows for glucokinase to have two distinct catalytic cycles (termed "fast" and "slow," respectively) and that the ratio of glucokinase in each of the two cycles is determined by the glucose concentration and accounts for the sigmoidal kinetics of glucokinase. Thus, at low glucose concentrations, the majority of glucokinase will enter the "slow" cycle that cycles through the inactive super open configuration; whereas at higher glucose concentrations, the majority of glucokinase will favor the fast cycle through the closed and open conformations and avoid the super open conformation (26) . GKAs shift the equilibrium between the two cycles in favor of the fast kinetic cycle and stabilize glucokinase in the active form (48) . This will account for a reduced S 0.5 ; however, the GKAs all have different activating properties. All of the known GKAs decrease the S 0.5 of glucokinase for glucose, and some, but not all, also increase V max . It is therefore notable that GKA50 does not increase V max . Hence, there must be various subtle effects on glucokinase conformation caused by the different GKAs. Regardless of the exact kinetic changes brought about by the different GKAs, the end result is a lowering of plasma glucose brought about by increased insulin secretion and/or increased hepatic glucose metabolism. With the data presented here, GKA50 has now been shown to significantly increase both parameters (25, 32) .
In conclusion, we have shown for the first time that an activator of glucokinase, GKA50, acts as a Ca 2ϩ -mediated glucose-dependent insulin secretagogue in human and rodent islets. No changes in intracellular Ca 2ϩ or insulin release were seen in the absence of glucose, and GKA50 cannot alone initiate insulin release. In man, we would expect GKA50 to cause a similar leftward shift in the EC 50 value for glucose in insulin secretion, and in type 2 diabetic islets, this would translate into both an increase in GSIS and normalization of the rightward-shifted glucose dose-response profile seen in these islets. These data therefore further support a role for GKAs as novel utilities in the therapeutic management of diabetes.
